Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Sponsorship Statement: This continuing education activity is sponsored by 
.
Support Statement: There is no commercial support for this activity. The content contained in this activity was developed from the Enduring Material that was supported by educational grants from 
.
Target Audience: The intended audience for the activities is retina specialists and other healthcare professionals involved in the treatment of patients with retina disorders.
Learning Objectives: At the conclusion of this activity participants should be able to:
- Examine the mechanisms of action of anti-vascular endothelial growth factor (VEGF) agents, steroids, and other medical therapies used in ophthalmic practice for the treatment of retinal disease.
- Utilize effective treatment approaches for medical diseases of the retina that best serve the individual patient’s diagnosis, needs, values and goals.
- Incorporate the most current evidence-based and clinical expert-based treatment recommendations into practice for the management of vision-threatening retinal disorders.
- Identify the most recent evidence-based and expert clinician-based treatment recommendations for specific vision-threatening retinal disorders.
Contributing Faculty:
Carmen A. Puliafito, MD, MBA (Planning Committee)
Retina/Vitreous Section Editor
OCULAR SURGERY NEWS
Dean, Keck School of Medicine
Professor of Ophthalmology
and Health Management
May S. and John Hooval Dean’s Chair in Medicine
University of Southern California
Los Angeles, California
Carlos Alexandre de A. Garcia Filho, MD
Bascom Palmer Eye Institute
Miami, Florida
Philip J. Rosenfeld, MD, PhD
Professor of Ophthalmology
Bascom Palmer Eye Institute
Miami, Florida
External Reviewer:
Mitchell A. Goff, MD
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 1, 2012 to December 1, 2013.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, read the article, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Planning Committee and Faculty members report the following relationship(s):
Carmen A. Puliafito, MD (Planning Committee)
Grants/Research Support: Carl Zeiss Meditec
Carlos Alexandre de A. Garcia Filho, MD
No relevant financial relationships to disclose.
Philip J. Rosenfeld, MD, PhD
Consulting Fees: Acucela, Canon, Inc., Cheng-du Kanghong Biotech, Oraya, ThromboGenics
Contracted Research: Alexion, Carl Zeiss Meditec, GlaxoSmithKline
Fees from Non-CME Services: Carl Zeiss Meditec
External Reviewer reports the following relationship(s):
Mitchell A. Goff, MD
Fees from Non-CME Services: Allergan, Genentech
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2012 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.